About Restem
Restem is a company based in Corona (United States) founded in 2016 by Rafael Gonzalez. It operates as a B2B. Restem offers products and services including Restem-L, rESTEM-x, and NK Program. Restem operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Corona, United States
- Founders Rafael Gonzalez
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Restem
Restem offers a comprehensive portfolio of products and services, including Restem-L, rESTEM-x, and NK Program.
Uses stem cells to treat idiopathic inflammatory myopathies.
Develops advanced cell-based treatments for various diseases.
Applies activated NK cells for immune response modulation.
People of Restem
Unlock access to complete
Unlock access to complete
Funding Insights of Restem
Detailed funding history for Restem
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Restem
Investment portfolio details for Restem
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Restem
Detailed financials for Restem
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Restem Comparisons
Peer comparison for Restem
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Restem
Restem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| Locked | Locked | Locked |
CRAC channel inhibitors are developed for inflammatory diseases.
|
Detailed competitors of Restem
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Restem
Complete news archive for Restem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Restem
Restem was founded in 2016.
Restem is headquartered in Corona, United States. It is registered at Corona, California, United States.
Restem specializes in harnessing umbilical cord lining stem cells and activated NK cells to modulate immune responses and treat diseases like idiopathic inflammatory myopathy and rheumatoid arthritis. The company conducts clinical trials, holds FDA designations, and focuses on scalable, off-the-shelf therapeutics. Based in the United States, Restem builds on 17 years of research to address global autoimmune challenges with innovative science and manufacturing capabilities.
Restem's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Restem offers Restem-L, rESTEM-x, and NK Program.